JOHNSON & JOHNSON
JOHNSON & JOHNSON (JNJ) Stock News
The latest JNJ headlines and market coverage — 3 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
NANOBIOTIX ANNONCE LA PRÉSENTATION DE DONNÉES DE LA PREMIÉRE PARTIE DE L’ÉTUDE CLINIQUE RANDOMISÉE DE PHASE 2 EVALUANT JNJ-1900 (NBTXR3) DANS LES CANCERS DU POUMON DE STADE 3 INOPÉRABLE
Nanobiotix announced early results from the Phase 2 CONVERGE study evaluating JNJ-1900 (NBTXR3), a nanoradioenhancer developed in collaboration with Johnson & Johnson, in patients with stage 3 inoperable non-small cell lung cancer. The study showed promising efficacy with an 85.7% overall response rate and 57.1% complete response rate in 7 patients who completed treatment, compared to less than 5% complete response rates with current standard of care.
- GlobeNewswire Inc.·
Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
Nanobiotix announced promising Part 1 data from the CONVERGE Phase 2 study evaluating JNJ-1900 (NBTXR3), a nanoradioenhancer, in stage 3 inoperable non-small cell lung cancer. Results showed an 85.7% overall response rate and 57.1% complete response rate in 7 patients receiving the treatment combined with concurrent chemoradiotherapy and durvalumab, significantly exceeding the <5% complete response rate of standard care.
- Yahoo Finance·Neutral
Johnson & Johnson (JNJ): Growth Engine at a Value Price